IBDEI20U ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,35338,0)
 ;;=I69.090^^186^2033^9
 ;;^UTILITY(U,$J,358.3,35338,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35338,1,3,0)
 ;;=3^Apraxia following nontraumatic subarachnoid hemorrhage
 ;;^UTILITY(U,$J,358.3,35338,1,4,0)
 ;;=4^I69.090
 ;;^UTILITY(U,$J,358.3,35338,2)
 ;;=^5007420
 ;;^UTILITY(U,$J,358.3,35339,0)
 ;;=I69.890^^186^2033^10
 ;;^UTILITY(U,$J,358.3,35339,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35339,1,3,0)
 ;;=3^Apraxia following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,35339,1,4,0)
 ;;=4^I69.890
 ;;^UTILITY(U,$J,358.3,35339,2)
 ;;=^5007546
 ;;^UTILITY(U,$J,358.3,35340,0)
 ;;=I69.290^^186^2033^11
 ;;^UTILITY(U,$J,358.3,35340,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35340,1,3,0)
 ;;=3^Apraxia following other nontraumatic intracranial hemorrhage
 ;;^UTILITY(U,$J,358.3,35340,1,4,0)
 ;;=4^I69.290
 ;;^UTILITY(U,$J,358.3,35340,2)
 ;;=^5007484
 ;;^UTILITY(U,$J,358.3,35341,0)
 ;;=I69.990^^186^2033^12
 ;;^UTILITY(U,$J,358.3,35341,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35341,1,3,0)
 ;;=3^Apraxia following unspecified cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,35341,1,4,0)
 ;;=4^I69.990
 ;;^UTILITY(U,$J,358.3,35341,2)
 ;;=^5007568
 ;;^UTILITY(U,$J,358.3,35342,0)
 ;;=I69.91^^186^2033^13
 ;;^UTILITY(U,$J,358.3,35342,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35342,1,3,0)
 ;;=3^Cognitive deficits following unsp cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,35342,1,4,0)
 ;;=4^I69.91
 ;;^UTILITY(U,$J,358.3,35342,2)
 ;;=^5007552
 ;;^UTILITY(U,$J,358.3,35343,0)
 ;;=I69.322^^186^2033^14
 ;;^UTILITY(U,$J,358.3,35343,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35343,1,3,0)
 ;;=3^Dysarthria following cerebral infarction
 ;;^UTILITY(U,$J,358.3,35343,1,4,0)
 ;;=4^I69.322
 ;;^UTILITY(U,$J,358.3,35343,2)
 ;;=^5007493
 ;;^UTILITY(U,$J,358.3,35344,0)
 ;;=I69.122^^186^2033^15
 ;;^UTILITY(U,$J,358.3,35344,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35344,1,3,0)
 ;;=3^Dysarthria following nontraumatic intracerebral hemorrhage
 ;;^UTILITY(U,$J,358.3,35344,1,4,0)
 ;;=4^I69.122
 ;;^UTILITY(U,$J,358.3,35344,2)
 ;;=^5007429
 ;;^UTILITY(U,$J,358.3,35345,0)
 ;;=I69.222^^186^2033^17
 ;;^UTILITY(U,$J,358.3,35345,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35345,1,3,0)
 ;;=3^Dysarthria following oth nontraumatic intcrn hemorrhage
 ;;^UTILITY(U,$J,358.3,35345,1,4,0)
 ;;=4^I69.222
 ;;^UTILITY(U,$J,358.3,35345,2)
 ;;=^5007461
 ;;^UTILITY(U,$J,358.3,35346,0)
 ;;=I69.022^^186^2033^16
 ;;^UTILITY(U,$J,358.3,35346,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35346,1,3,0)
 ;;=3^Dysarthria following nontraumatic subarachnoid hemorrhage
 ;;^UTILITY(U,$J,358.3,35346,1,4,0)
 ;;=4^I69.022
 ;;^UTILITY(U,$J,358.3,35346,2)
 ;;=^5007397
 ;;^UTILITY(U,$J,358.3,35347,0)
 ;;=I69.822^^186^2033^18
 ;;^UTILITY(U,$J,358.3,35347,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35347,1,3,0)
 ;;=3^Dysarthria following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,35347,1,4,0)
 ;;=4^I69.822
 ;;^UTILITY(U,$J,358.3,35347,2)
 ;;=^5007524
 ;;^UTILITY(U,$J,358.3,35348,0)
 ;;=I69.922^^186^2033^19
 ;;^UTILITY(U,$J,358.3,35348,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35348,1,3,0)
 ;;=3^Dysarthria following unspecified cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,35348,1,4,0)
 ;;=4^I69.922
 ;;^UTILITY(U,$J,358.3,35348,2)
 ;;=^5007555
 ;;^UTILITY(U,$J,358.3,35349,0)
 ;;=I69.391^^186^2033^20
 ;;^UTILITY(U,$J,358.3,35349,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35349,1,3,0)
 ;;=3^Dysphagia following cerebral infarction
 ;;^UTILITY(U,$J,358.3,35349,1,4,0)
 ;;=4^I69.391
 ;;^UTILITY(U,$J,358.3,35349,2)
 ;;=^5007516
 ;;
 ;;$END ROU IBDEI20U
